Seeking Alpha

Colfax Capital is distinctly unimpressed by Oncothyreons (ONTY) development deal with Array....

Colfax Capital is distinctly unimpressed by Oncothyreons (ONTY) development deal with Array. "What a lousy company," Colax tweets. "Now inlicensing other compounds from ARRY while they inlicensed a Bcl last year that is collecting dust." The market is yet to pass its judgement.
Comments (1)
  • ed naples
    , contributor
    Comments (4) | Send Message
     
    Is Colfax Capital Shorting Onty?
    30 May 2013, 03:59 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|